Navigation Links
Botaneco obtains $2.4 million in funding from AVAC
Date:10/17/2007

TSX symbol: SBS

CALGARY, Oct. 17 /PRNewswire-FirstCall/ - Botaneco, a business unit of SemBioSys Genetics Inc. (TSX:SBS), today announced that it has reached an agreement with AVAC Ltd. for $2.4 million in non-dilutive funding for the development of Botaneco as an independent business. The funding will be paid in installments over a 27-month period, beginning in the fourth quarter of 2007, upon the formation of Botaneco as a separate legal entity and the execution of development and commercial milestones.

"We believe this funding will contribute towards our strategy for Botaneco to operate independent of SemBioSys and provide the opportunity for it to grow and advance its commercial strategy. With the recent commissioning of the commercial manufacturing facility and the launch of Botaneco's Hydresia(TM) product earlier this month, the AVAC funding will allow us to continue the momentum we are building with the Botaneco business," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "Historically, AVAC has supported a number of programs at SemBioSys and their commitment to Botaneco demonstrates the opportunity we believe exists for our oilbody-oleosome technology in the personal care and topical ingredients market."

In return for the funding, Botaneco has agreed to provide AVAC a modest royalty, by industry standards, beginning in December 2009 on all gross revenues derived by Botaneco in arrears until an aggregate return up to a maximum of two times the gross amount invested by AVAC has been remitted.

About Botaneco (http://www.botaneco.ca)

Botaneco, a business unit of SemBioSys, will manufacture and market branded lines of high performance, naturally derived base emulsions and delivery systems used in the development of cosmetics, personal care and prescription topical/dermatology products. Botaneco is leveraging SemBioSys' proprietary technology, a first-in-class, all-in-one system for emulsification, skin barrier protection and superior hydration and absorption of nutrient rich moisturizers and emollients as well as enhanced performance of skincare actives.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.

About AVAC (http://www.avacltd.com)

AVAC Ltd. is a not-for-profit company dedicated to accelerating the growth of agrivalue(TM) in Alberta. AVAC invests in innovation ideas that add value to agricultural commodities through coaching, knowledge, contacts and financial resources. AVAC's mission is to help accelerate the growth of agrivalue(TM) in Alberta. Created in 1997, AVAC has to date committed over $43,000,000 to agrivalue(TM) initiatives.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
3. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
4. TomoTherapy raises $223 million in IPO
5. Fiserv reports $113.5 million in Q1 profit
6. Investors raise $25 million for biodiesel plant
7. Grow Milwaukee includes millions for tech funding
8. Mirus Bio, Pfizer enter multimillion-dollar research agreement
9. ConjuGon raises $3.3 million to fund clinical trials
10. TrafficCast secures $1 million line of credit
11. Make Mine a $Million shoots for May program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):